Thioridazine pharmacodynamics: Clinical effects may depend upon drug metabolism

M. H. Lewis, J. N. Mobilio, D. J. Rissmiller, Richard Mailman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The clinical effects of the phenothiazine antipsychotic, thioridazine (Mellaril), appear to depend in large measure on the biotransformation of the parent drug to biologically active metabolites. This review presents in vitro and in vivo data suggesting that the S-oxidized metabolites of thioridazine have potent antidopaminergic activity. Moreover, in studies with hamsters, a species that metabolizes thioridazine in a manner similar to humans, thioridazine was shown to have potent effects on basal ganglia dopamine. Also, contrary to earlier reports, thioridazine was not found to display a greater effect on mesolimbic versus basal ganglia dopamine in either rats or hamsters. These results suggest that thioridazine may not have 'atypical' actions in humans and may not place patients at a reduced risk for tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)124-128
Number of pages5
JournalJournal of the American Osteopathic Association
Volume84
Issue number1 SUPPL.
StatePublished - Jan 1 1984

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Fingerprint Dive into the research topics of 'Thioridazine pharmacodynamics: Clinical effects may depend upon drug metabolism'. Together they form a unique fingerprint.

Cite this